Article Sidebar

pdf
Date Published: 02/12/2025
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v556i1.16271
Issue
Vol. 556 No. 1 (2025)
Section
Các bài báo
How to Cite
Lê, N. A., Nguyễn, T. T. M., Trần, T. Đạt, & Ngụy, T. Điệp. (2025). PRELIMINARY STUDY ON PLASMA sTNFR2 LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE AT HANOI NEPHROLOGY HOSPITAL. Vietnam Medical Journal, 556(1). https://doi.org/10.51298/vmj.v556i1.16271

PRELIMINARY STUDY ON PLASMA sTNFR2 LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE AT HANOI NEPHROLOGY HOSPITAL

Ngọc Anh Lê, Thị Thúy Mậu Nguyễn, Tiến Đạt Trần, Thị Điệp Ngụy

Main Article Content

Abstract

Soluble tumor necrosis factor receptor 2 (sTNFR2), which reflects inflammation and renal injury in diabetic patients, may serve as a potential biomarker. This study aimed to evaluate plasma sTNFR2 levels and related factors in type 2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD). A cross-sectional study was conducted on 80 patients with T2DM at Hanoi Nephrology Hospital. Patients were categorized into four groups based on their stages of CKD. Plasma sTNFR2 levels were quantified by ELISA. Results: Plasma sTNFR2 levels progressively increased with advancing stages of CKD: 1.967 ng/mL (no CKD), 1.584 ng/mL (CKD stage 1&2), 8.725 ng/mL (CKD stage 3), and 15.198 ng/mL (CKD stage 4) (p<0.001). sTNFR2 correlated strongly and inversely with eGFR (rho = –0.716, p<0.001) and positively with serum creatinine (rho = 0.674, p<0.001), serum urea (rho = 0.596, p<0.001), and proteinuria (rho = 0.497, p<0.001). ROC curve analysis demonstrated good discriminative ability of sTNFR2 for identifying eGFR <60 ml/min/1.73m² with an AUC of 0.875 (p<0.0001). A diagnostic cutoff of 6.117 ng/mL yielded 78.6% sensitivity and 89.5% specificity. Conclusion: Plasma sTNFR2 levels were markedly elevated in T2DM patients with CKD, particularly at advanced stages, and were strongly correlated with renal function decline. These finddings suggest that sTNFR2 may represent a promising biomarker for assessing and monitoring the prognosis of diabetic kidney disease

Article Details

Keywords

: sTNFR2, chronic kidney disease, type 2 diabetes mellitus

References

1. Hussain S, Chand Jamali M, Habib A, et al. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clin Epidemiol Glob Health. 2021; 9:2-6.
2. Trịnh Quốc Khởi và cộng sự. Tỷ lệ đái tháo đường týp 2 có biến chứng thận và thực trạng phòng, chống biến chứng thận ở bệnh nhân đái tháo đường týp 2 tại bệnh viện đa khoa Cái Nước năm 2022-2023. Tạp chí y học Việt Nam. 2024;536(1B).
3. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302-308.
4. Tsalamandris S, Antonopoulos AS, Oikonomou E, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol Rev. 2019;14(1):50-59.
5. Awad AS, You H, Gao T, et al. Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury. Kidney Int. 2015;88(4):722-733.
6. Carlsson AC, Östgren CJ, Nystrom FH, et al. Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes. Cardiovasc Diabetol. 2016; 15:40.
7. Wu TH, Chang LH, Chu CH, Hwu CM, Chen HS, Lin LY. Soluble tumor necrosis factor receptor 2 is associated with progressive diabetic kidney disease in patients with type 2 diabetes mellitus. PLoS ONE. 2022;17(4): e0266854.
8. Waijer SW, Sen T, Arnott C, et al. Association between
9. Đánh giá chất lượng cuộc sống bệnh nhân TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2022;17(2):251-259.